Gilead Sciences stock keeps Hold rating, falls slightly pre-market
Published on 10/22/2026 at 08:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst view and morning setup
- RBC Capital analyst Brian Abrahams maintained a Hold rating and set a USD 126.00 target on October 21, 2026.
- Gilead's business covers virology, oncology and inflammation.
- Gilead Sciences stock trades pre-market at EUR 136.25 at 8:22 a.m. CEST at Lang & Schwarz on October 22, 2026, 0.31 percent below the Xetra close of October 21, 2026.
On October 21, 2026, RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences and set a USD 126.00 price target, according to Markets Insider. Gilead Sciences stock trades pre-market at EUR 136.25 at 8:22 a.m. CEST at Lang & Schwarz on October 22, 2026, 0.31 percent below the Xetra close of October 21, 2026 (EUR 136.68).
RBC keeps a Hold rating
The analyst action was reported on October 21, 2026. The report also cited a broader average price target of USD 160.20, while RBC Capital's target for Gilead was USD 126.00. The figures were reported by Markets Insider, which identified Brian Abrahams as the RBC Capital analyst covering the company.
Ahead of the Xetra open
At Lang & Schwarz, the stock stood EUR 0.43 below the Xetra close of October 21, 2026, equivalent to the stated percentage difference. The bid was EUR 135.50 and the ask EUR 137.00, a spread of 1.10 percent. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Gilead Sciences stock.
Gilead's business and market
Gilead develops medicines in virology, oncology and inflammation, according to the company's website. Its website describes a pipeline spanning those therapeutic areas and provides investor-relations resources. Market context: Market report Nasdaq Composite.
